Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Gabe Fernandez who wrote (1074)	3/6/2000 8:54:00 PM
From: LTK007	Respond to of 1386

insider selling as studied by WSJ is an inferior indicator--that's all i have to say.max

To: Gabe Fernandez who wrote (1074)	3/6/2000 9:08:00 PM
From: LTK007	Read Replies (1) \| Respond to of 1386

Gabe,is this what you are refering,it is all to the good--this taken from todays PARS press release <<Pharmos also announced today that it has completed a second round of financing by taking down the remaining unallocated shares of its shelf registration, raising an additional $5.5 million in gross proceeds. The shares were sold at prices ranging from $2.50 to $6.25. Combined with the previously reported $7.3 million financing, the Company raised a total of $12.8 million in this exercise. ``We felt it was extremely important to take quick advantage of the improvement in the Company's stock price,' said Robert W. Cook, Pharmos Vice President Finance and CFO. ``The stock price's upward movement afforded us a great opportunity to lock in funding to support the Company's development programs while our ophthalmic revenues continue their steady growth. Now, in addition to the clinical development of dexanabinol for traumatic brain injury, we can put more resources behind our dexanabinol analog and SERM discovery programs.'>>